‘Off-the-Shelf’ Immunotherapy: Manufacture of CD8+ T Cells Derived from Hematopoietic Stem Cells
Cellular immunotherapy is revolutionizing cancer treatment. However, treatments created from each patient’s cells are complex, costly, and limited by the number and quality of killer T cells that can be isolated from and expanded for re-infusion into each patient.
In this […]
By Leigh Dayton
7 October 2021
According to Cartherics CEO Alan Trounson, taking ideas from the laboratory to the marketplace is a “long and tortuous process”. First-hand experience goes far towards identifying and navigating the hurdles of research translation.
And experience – from pioneering work in IVF and embryonic stem cell science […]
On Thursday, 2 September, in an interview with Jack Hodgins on 2NUR.FM’s ‘Wellbeing’ segment, Professor Bryan Williams (Cartherics Non-Executive Board Member) spoke about COVID-19, viruses and how vaccines control them, and the importance of medical research.
“I would encourage Australians to convince their politicians that they need to increase the research budget in Australia, […]
By Leigh Dayton
27 August 2021
Cartherics CEO Alan Trounson congratulates Natalia Benetti for her important research in developmental cell biology: “It’s great work and very well presented”.
The company also applauds the Australian Regenerative Medicine Institute for successfully organising the 13th Victorian State Conference of the […]
By Leigh Dayton
9 August 2021
Cartherics is pleased to announce that CEO Alan Trounson has been congratulated by the National Library of Australia for his recognition on this year’s Queen’s Birthday Honours List.
In recognition of his “distinguished service to medical science, and to in vitro fertilisation and stem cell technologies” Trounson was appointed an […]
By Leigh Dayton
22 July 2021
Cartherics is delighted to announce that it is a sponsor of the Australia and New Zealand Society of Cell and Developmental Biology’s Victorian State Conference. The highly regarded one-day event is booked for 26 August at the University of Melbourne.
Cartherics CEO Alan Trounson welcomes the opportunity to support the meeting.
“It is […]
Cartherics Pty Ltd and the Australian Regenerative Medicine Institute (ARMI), including commercialisation initiative CCRM Australia, announced agreements for closer cooperation and collaboration today.
“Cartherics affiliation with ARMI is an important step in our development and will embed industry and academic excellence in regenerative medicine and translation to clinical medicine in cancer,” said Prof Alan Trounson, Cartherics […]
Melbourne, Australia and Seoul, South Korea
28 June 2021
Cartherics Pty Ltd (“Cartherics”) and ToolGen, Inc. (“ToolGen”) announced today that they have entered into a commercial licence agreement.
Under the agreement, Cartherics obtains […]
By Heather Hawkins
24 May 2021
Even today – and it’s been 14 years since diagnosis – they still evoke a very raw and deeply emotional response. It was the first time I’d faced the undeniable fact […]
Four Australian women are diagnosed with ovarian cancer a day and three will eventually die from the disease. It’s usually diagnosed late, because few women show symptoms until they have advanced cancer.
As a junior doctor in London in the mid-1980s, Ian Jacobs saw women undergo chemo and […]
Cartherics’ mission is the development of novel, “off-the-shelf” (allogeneic) immune cell therapy products for the treatment of cancer.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
